Neddylation as a target in PIK3CA-mutated head and neck cancer
- 26 March 2025
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 759, 151703
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Dental and Craniofacial Research (R015R01DE023685)
- National Institutes of Health
- Division of Cancer Prevention, National Cancer Institute (R35CA231998)
This publication has 26 references indexed in Scilit:
- The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancerAdvances in Biological Regulation, 2022
- Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neckOral Oncology, 2020
- Targeting Protein Neddylation for Cancer Therapy2020
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2018
- Synthetic lethality and cancerNature Reviews Genetics, 2017
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- Comprehensive genomic characterization of head and neck squamous cell carcinomasNature, 2015
- Genome-Scale CRISPR-Mediated Control of Gene Repression and ActivationCell, 2014
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumoursBritish Journal of Cancer, 2013
- CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in EukaryotesCell, 2013